The National Heart, Lung, and Blood Institute (NHLBI) awarded a $688,800 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Albert Einstein College of Medicine in Bronx, NY. The grant, which runs from July 1, 2024 to June 30, 2028, will support research to define the mechanisms by which the transcription factor RUNX1 cooperates with other regulatory proteins to control gene expression programs critical for normal hematopoiesis and how disruption of these programs contributes to the development of familial platelet disorder and myeloid malignancies. The research will utilize RUNX1 degron technology to rapidly deplete RUNX1 and study the resulting transcriptional changes in cell line and mouse models, with the goal of providing mechanistic insights into the molecular underpinnings of RUNX1-related hematological disorders.
Generated 3/4/25, 6:24 AM